Clinical trials: Carboplatin, open to volunteers
Ovarian Cancer Recurrent
A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003).
Researchers are looking for other ways to treat high-grade serous and certain other ovarian cancer. High-grade means the cancer cells grow and spread quickly.
- Trial name
- NCT06843447
- Testing
- Raludotatug Deruxtecan, Carboplatin, Paclitaxel
- Where
- 39 sites in United States, Canada and 6 more
- Volunteers
- 605 people
- Sponsor
- Merck Sharp & Dohme LLC
Non-Small Cell Lung Cancer (NSCLC)
MRD and Imaging Guided Adaptive Neoadjuvant Therapy for Resectable NSCLC
Neoadjuvant immunotherapy combined with platinum-based doublet chemotherapy has been established as the standard of care for driver-gene-negative (EGFR/ALK wild-type) stage II-IIIB non-small cell lung cancer (NSCLC), yielding…
- Trial name
- NCT07885709
- Testing
- PD-1 inhibitor, Carboplatin, Nab-paclitaxel
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Peking University People's Hospital
Non Small Cell Lung Carcinoma, c-MET
Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
Non small cell lung carcinoma (NSCLC) is the most frequently occurring histologic subtype of lung cancer and is the leading cause of cancer-related deaths worldwide.
- Trial name
- NCT06772623
- Testing
- Telisotuzumab Adizutecan, Budigalimab, Pembrolizumab
- Where
- 126 sites in United States, Argentina and 14 more
- Volunteers
- 252 people
- Sponsor
- AbbVie
Epithelial Ovarian Cancer, Fallopian Tube Cancer
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess the safety and efficacy of neoadjuvant carboplatin and mirvetuximab soravtansine in…
- Conditions
- Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Neoadjuvant
- Trial name
- NCT06890338
- Testing
- Carboplatin, Mirvetuximab Soravtansine, Bevacizumab
- Where
- 73 sites in United States
- Volunteers
- 140 people
- Sponsor
- AbbVie
Breast Neoplasms
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
This is a Phase III trial where participants will be randomized to two treatment groups, which means participants will be assigned by equal chance to a treatment group.
- Trial name
- NCT07173751
- Testing
- Pumitamig, Nab-paclitaxel/Paclitaxel, Gemcitabine
- Where
- 217 sites in United States, Argentina and 17 more
- Volunteers
- 558 people
- Sponsor
- BioNTech SE
Small Cell Lung Cancer Extensive Stage
A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)
Researchers are looking for new ways to treat extensive-stage small cell lung cancer (ES-SCLC). ES-SCLC is a type of lung cancer that has spread throughout the lung, to the other lung, or to other parts of the body.
- Trial name
- NCT07227597
- Testing
- Gocatamig, I-DXd, Atezolizumab
- Where
- 57 sites in United States, Argentina and 11 more
- Volunteers
- 170 people
- Sponsor
- Merck Sharp & Dohme LLC
Locally Advanced / Metastatic Solid Tumors
CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors
The purpose of this study is to determine the safety and tolerability of monotherapy CR-001 and identify the maximum tolerated dose (MTD), and/or optimal biologic dose and Recommended Phase 2 Dose(s) (RP2D) in participants with…
- Trial name
- ASCEND (NCT07335497)
- Testing
- CR-001, Paclitaxel, trifluridine and tipiracil
- Where
- 34 sites in United States, Australia and 7 more
- Volunteers
- 540 people
- Sponsor
- Crescent Biopharma, Inc.
Non Small Cell Lung Cancer (Squamous or Non Squamous), Stage 4 NSCLC
A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.
This is a study to evaluate the safety and efficacy of EIK1001 administered intravenously in combination with pembrolizumab and histologically appropriate chemotherapy for patients with stage 4 NSCLC.
- Trial name
- TeLuRide-008 (NCT07365319)
- Testing
- EIK1001, Pembrolizumab (KEYTRUDA®), Paclitaxel + Carboplatin
- Where
- 32 sites in United States, Australia and 7 more
- Volunteers
- 750 people
- Sponsor
- Eikon Therapeutics
Small Cell Lung Cancer (SCLC), Extensive-stage Small Cell Lung Cancer (ES-SCLC)
DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy
This study is open to adults with advanced small cell lung cancer (SCLC). The purpose of this study is to find out if a study medicine called obrixtamig plus standard treatment (atezolizumab, carboplatin, and etoposide) improves…
- Trial name
- NCT07472517
- Testing
- obrixtamig, atezolizumab, carboplatin
- Where
- 245 sites in United States, Argentina and 40 more
- Volunteers
- 670 people
- Sponsor
- Boehringer Ingelheim
Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma, Recurrent Platinum-Sensitive Fallopian Tube High Grade Serous Adenocarcinoma
Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance Therapy
This phase II trial compares the effect of sacituzumab govitecan and bevacizumab to standard care (carboplatin, pegylated liposomal doxorubicin, and bevacizumab) in patients with ovarian cancer that has come back after an initial…
- Conditions
- Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma, Recurrent Platinum-Sensitive Fallopian Tube High Grade Serous Adenocarcinoma, Recurrent Platinum-Sensitive Ovarian High Grade Endometrioid Adenocarcinoma, Recurrent Platinum-Sensitive Ovarian High Grade Serous Adenocarcinoma
- Trial name
- NCT07504588
- Testing
- Anti-VEGF Monoclonal Antibody, Bevacizumab, Biospecimen Collection
- Where
- 13 sites in United States
- Volunteers
- 87 people
- Sponsor
- National Cancer Institute (NCI)
Non-Small Cell Lung Cancer
A Study to Assess Intravenous ABBV-1480 Combined With Chemotherapy Versus Pembrolizumab Combined With Chemotherapy for the First Line Treatment of Locally Advanced/Metastatic Non-Small Cell Lung Cancer in Adult Participants
Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for 80%-85% of lung cancers cases. Squamous carcinoma accounts for 20-30% of all NSCLC cases.
- Trial name
- NCT07756645
- Testing
- ABBV-1480, Pembrolizumab, Carboplatin
- Where
- 2 sites in United States, Puerto Rico
- Volunteers
- 940 people
- Sponsor
- AbbVie
Non-Small Cell Lung Cancer, NSCLC, KRAS, NRAS, HRAS-mutated NSCLC
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
The purpose of this platform study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON) inhibitors as a monotherapy or combined with Standard(s) of Care (SOC) or with…
- Conditions
- Non-Small Cell Lung Cancer, NSCLC, KRAS, NRAS, HRAS-mutated NSCLC, KRAS G12C-mutated Solid Tumors, Lung Cancer, Lung Cancer Stage IV, Advanced Solid Tumor, Cancer
- Trial name
- NCT06162221
- Testing
- RMC-6291, RMC-6236, Pembrolizumab
- Where
- 98 sites in United States, Australia and 11 more
- Volunteers
- 616 people
- Sponsor
- Revolution Medicines, Inc.
Metastatic Non-Squamous Non-Small Cell Lung Cancer, Adult Solid Tumor
Trial Investigating Visugromab in Combination With Immunochemotherapy in 1L Treatment of Participants With Metastatic NSCLC
This is an exploratory, signal finding, randomized, placebo-controlled, blinded, multi-center Phase 2b trial of the anti GDF-15 antibody Visugromab (CTL-002) versus Placebo, combined with Immunochemotherapy (ICT: Pembrolizumab…
- Trial name
- NCT07098988
- Testing
- Visugromab, Pembrolizumab 200 mg Q3W, Pemetrexed 500 mg/m^2
- Where
- 51 sites in United States, Germany and 5 more
- Volunteers
- 107 people
- Sponsor
- CatalYm GmbH
Advanced Extrapulmonary Neuroendocrine Carcinoma
A Trial of LBL-024 Combined With Platinum-based Chemotherapy for the Treatment of Advanced EP-NEC
This trial is a randomized, double-blind, placebo-controlled multicenter phase III clinical study aiming to evaluate the efficacy and safety of LBL-024 compared with placebo in combination with etoposide and cisplatin or…
- Trial name
- NCT07720193
- Testing
- LBL-024 for Injection, Etoposide injection, Cisplatin injection
- Where
- 36 sites in China
- Volunteers
- 280 people
- Sponsor
- Nanjing Leads Biolabs Co.,Ltd
Endometrial Carcinoma, Neoplasms, Endometrial
Two Part (Phase1b/ Phase3) Trial of Subcutaneous Dostarlimab Plus Carboplatin-Paclitaxel in Participants With Primary Advanced or Recurrent Endometrial Cancer
This is an open-label study, meaning both the researchers and participants will know which treatment is being given. The study has two parts. In Part 1, researchers will identify the most suitable SC dose.
- Trial name
- SAPPHIRE (NCT07860450)
- Testing
- Dostarlimab, Carboplatin and paclitaxel
- Volunteers
- 378 people
- Sponsor
- GlaxoSmithKline
Triple Negative Breast Cancer
A Study of SYS6043 Versus Investigator's Choice Chemotherapy as First-Line Treatment in Patients With Unresectable Locally Recurrent or Metastatic Triple-Negative Breast Cancer
This is a randomized, controlled, open-label, multicenter study. Eligible participants are patients with unresectable locally recurrent or metastatic triple-negative breast cancer (TNBC) who have not received prior systemic…
- Trial name
- NCT07879911
- Testing
- Enter a brief, descriptive name for the intervention. Use a non-proprietary (generic) name, if available. SYS6043, Investigator's Choice of Chemotherapy (paclitaxel，nab paclitaxel，capecitabine，eribulin，carboplatin）
- Volunteers
- 550 people
- Sponsor
- CSPC Megalith Biopharmaceutical Co.,Ltd.
SCLC
A Study of ZL-1310 in Subjects With Small Cell Lung Cancer
An open-label, multicenter study of ZL-1310 as a single agent and in combination with Atezolizumab (with and without Carboplatin) to evaluate the safety, efficacy, and pharmacokinetics in subjects with small cell lung cancer
- Trial name
- NCT06179069
- Testing
- ZL-1310, Atezolizumab, Carboplatin
- Where
- 41 sites in United States, China and 2 more
- Volunteers
- 339 people
- Sponsor
- Zai Lab (Shanghai) Co., Ltd.
Ovarian Neoplasm Epithelial, Fallopian Tube Neoplasms
OV Precision: Study Examining the Benefit of a Tumor- and Patient-specific Cancer Therapy
The long-term goal of this research project is to demonstrate whether HRD negative (HPDneg) patients benefit when additional multi-modal biological tumor information is incorporated into the molecular tumor board (mTB) treatment…
- Conditions
- Ovarian Neoplasm Epithelial, Fallopian Tube Neoplasms, Ovarian Endometrioid Carcinoma, High-grade Serous Ovarian Carcinoma (HGSOC)
- Trial name
- OVPrecision (NCT06466382)
- Testing
- Treatment recommendation by molecular tumorboard (mTB) based on tumor profiling, Carboplatin / Paclitaxel Chemotherapy
- Where
- 10 sites in Switzerland
- Volunteers
- 135 people
- Sponsor
- Swiss GO Trial Group
Carcinoma, Non-Small-Cell Lung
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
The goal of this study is to learn if people who receive intismeran autogene and pembrolizumab after surgery are cancer-free longer than people who receive placebo and pembrolizumab.
- Trial name
- NCT06623422
- Testing
- Pembrolizumab, Cisplatin, Carboplatin
- Where
- 244 sites in United States, Argentina and 29 more
- Volunteers
- 680 people
- Sponsor
- Merck Sharp & Dohme LLC
Non-small Cell Lung Cancer
A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01)
Researchers are investigating new treatments for untreated advanced non-small cell lung cancer (NSCLC), which is the most common form of lung cancer and lung cancer that has spread beyond surgical removal.
- Trial name
- NCT06731907
- Testing
- Pembrolizumab, Carboplatin, Paclitaxel
- Where
- 41 sites in United States, Chile and 9 more
- Volunteers
- 90 people
- Sponsor
- Merck Sharp & Dohme LLC